European healthcare economists get nasty about UK NICE and the QALY
This article was originally published in SRA
The quality-adjusted life years (QALY)-based approach used by NICE, the health technology appraisal institute for England and Wales, is heavily flawed and should not be adopted by other European member states, warns a European Commission-sponsored project1. The four main assumptions underpinning the QALY about how patients value additional life gain and different health states are invalid, according to the survey. "Everything it is based upon is wrong," said Ariel Beresniak, leader of the project which reported its results at a symposium in Brussels on 25 January.
You may also be interested in...
A Dutch parallel registration and reimbursement pilot has brought benefits including more participation from healthcare professionals, and also forces company divisions to be less streamlined.
The UK’s withdrawal from the EU could upset the Unitary Patent Court project.
International reference pricing has created narrow price corridors that can limit access to medicines and vaccines in lower income countries. The issue will start to impact higher income EU markets if US plans to introduce IRP come to fruition.